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Abstract: Background Donor selection criteria are crucial for a successful lung transplant outcome. Our
objective was to develop a new donor score to predict short- and long-term survival and validate it with
five existing lung donor scores (Oto, Eurotransplant, Minnesota, Maryland-UNOS, Louisville-UNOS).
Methods All 454 adult lung transplants at our center between 1992-2015 were included to develop a
new score. Discriminative ability for all scores was calculated by the area under time-dependent receiver
operating characteristic curves (time-dependent AUC) at 30-day, 1, 5 and 10-year survival, and their
fit compared with Akaike’s information criterion. For the new score, five pre-selected donor risk factors
were derived: age, diabetes mellitus, smoking history, pulmonary infection, PaO2/FiO2-ratio, weighed via
simplification of a multiple Cox model, and shrinkage used to avoid overfitting. The score sub-weighting
resulted in a total of 17 points. Results The existing scores showed predictive accuracy better than
chance in prediction of survival of 5-year (AUC 0.58-0.60) to 10-year survival (AUC 0.58-0.64). Our
new score had better discriminative ability as the existing scores with regard to 1, 5 and 10-year survival
(AUC 0.59, 0.64, 0.66, respectively). Additional adjustment for recipient and surgical procedure variables
improved the time-dependent AUC’s slightly. For the secondary outcomes primary graft dysfunction and
bronchiolitis obliterans syndrome, the new score showed also a good predictive accuracy. Conclusions
The proposed Zurich Donor Score is simple, well adapted for the current urge of extended donors use, and
shows higher discriminative ability compared to preexisting donor scores regarding short- to long-term
survival.
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Introduction
Organ shortage and a  growing demand for  lung 
transplantations force several centers to increasingly use 
extended donor lungs. In 2003 the International Society 
for Heart and Lung Transplantation (ISHLT) released a 
consensus report (1) defining an ideal donor lung based 
on 5 variables: age <55, smoking history <20 pack years, 
uncompromised chest X-ray, clear bronchoscopy and 
pulmonary arterial oxygen tension/fraction of inspired 
oxygen-ratio >300 mmHg.
In the meantime, several attempts were made to further 
specify and identify potential extended criteria. In 2007 Oto 
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et al. (2) at the University of Melbourne suggested a score 
based on the ISHLT-criteria to predict donor selection and 
early post-lung-transplant outcome. In 2011 the Oto-Score 
was modified by the European allocation organization 
Eurotransplant (3) to a new score serving the same purpose. 
In 2016 the University of Minnesota (4) created a new, 
complex, consensus-based lung scoring system to predict 
lung offer acceptance and usability for transplantation. 
However, the University of Maryland (5) identified donor 
risk factors based on United Network for Organ Sharing 
(UNOS) data and created a single point score that was 
associated with one-year survival, based on just four 
simple risk factors. Lately, the University of Louisville (6) 
identified almost identical four risk factors in the same data 
base and showed an association with 1 and 5-year survival. 
To date, only the Oto-Donor-Score has been externally 
validated with inconsistent results (4,7). Except for the 
Louisville-UNOS donor score, nothing is known about the 
utility of any of these scores to predict long-term survival.
The goal of the current study was first, to validate the 
short- and long-term predictive ability of five published 
scores based on our centers transplant pool and second, 
to develop a new and simple donor score for survival 
that includes donor parameters prior to procurement. 
We present the following article in accordance with the 
TRIPOD reporting checklist (available at http://dx.doi.
org/10.21037/jtd-20-2043).
Methods
We performed a retrospective study of all adult recipients 
and their corresponding donors transplanted at the 
University Hospital of Zurich between 11/1992 and 
12/2015, with last follow-up in 10/2019. Donor and 
recipient data were collected retrospectively from 
prospectively entered medical records. For donor variables, 
the values at the time of donor acceptance, prior to 
procurement were used. Infection suspected on radiological 
findings in the contralateral lung were ignored in cases 
where only unilateral transplants were performed. The 
collected donor variables were compared to findings in 
the donor report at the time of procurement. The study 
has been approved by the Cantonal Ethics Committee 
Zurich (KEK-ZH-Nr.2013-0624), and the need to obtain 
informed consent was waived because of the retrospective 
observational nature of the study. This study was conducted 
in accordance with the Declaration of Helsinki (as revised 
in 2013).
Outcomes
The primary outcome was survival after lung transplantation. 
Secondary outcomes were primary graft dysfunction grade 
3 (PGD3) (8), defined as PaO2/FiO2-ratio <200 mmHg 
and the presence of diffuse parenchymal infiltrates 
in the allograft on chest radiograph at 72 hours after 
transplantation (binary outcome); as well as severe 
bronchiolitis obliterans syndrome grade III (BOS-III) (9), 
defined as a persistent decline of forced expiratory volume 
in 1 second (FEV1) ≤50% and an obstructive physiology 
(time-to-event).
Definition of predictor variables
Variables of the existing donor scores
The variables of the five existing donor scores are shown 
in Tables S1-S5. Oto-Score (2) consists of 5 subdivided 
donor criteria based on the ISHLT-Consensus Report (1). 
Eurotransplant-Score (3) is a simplified version of Oto-
Score with the addition of a compromised history. The 
University of Minnesota-Donor-Lung quality index (4) 
includes 17 subdivided factors of which one factor 
represents the recipient specific American Lung Allocation 
Score (LAS). As LAS is not used in Switzerland, we excluded 
LAS for this score but adjusted for recipient and surgical 
procedure variables subsequently. To make the results of 
the evaluation of the Minnesota score comparable to the 
results of the other scores, the scale was reversed such that 
higher values are associated with higher risk for mortality. 
University of Maryland-UNOS-data donor score (5) 
and Louisville-UNOS-data score (6) are very simple scores 
based on the same 4 variables, except that the later uses 
different breaks for age. 
Development of the Zurich-Donor-Score for prediction 
of mortality
A larger and preliminary set of potential risk variables was 
defined consisting of all variables of the five existing donor 
scores (Tables S1-S5) and availability. A preselection of 
variables was performed according to the estimated hazard 
ratios (HR) and P values from univariate Cox regression 
models with outcome survival. If the corresponding HR was 
≥1.2 and P value <0.2, the predictor variable was assumed 
to be relevant for risk prediction (10). The final set of 
variables used to develop the new donor score included 
the following variables: significant pulmonary infection, 
diabetes mellitus, PaO2/FiO2-ratio, smoking history in pack 
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years, and donor age. The three continuous variables were 
categorized by the study team according to multiple non-
linear graphical assessment using splines and consideration 
of the recent literature. After categorization of the 
continuous variables, all variables were coded as factor 
variables and their association with survival was assessed in 
a multiple Cox model. Resulting estimated beta-coefficients 
were shrinked globally to account for overfitting. Shrinkage 
is a statistical technique used in regression analysis, to avoid 
overfitting (11). Subsequently, the new score’s values were 
assigned following the rule that estimated beta-coefficients 
of 0.1 to 0.2 were assigned two points, such of 0.3 three 
points, such of 0.4 four points, and higher beta-coefficients 
five points. Score points were assigned in monotonous 
fashion with increasing category of risk factor. 
Definition of recipient- and surgical procedure variables
To consider the impact of  recipient and surgical 
procedure variables on post-transplant survival, we adjusted 
our models for the following risk factors that are well known 
from the literature and also present in our cohort: unilateral 
transplantation (12), retransplantation (12), idiopathic 
pulmonary fibrosis as underling disease (12), preoperative 
intensive care unit stay (12), recipient age (12), and for the 
comorbidity profile the age independent Charlson-Deyo 
Index (13). No additional impact was observed by adjusting 
for up to 3 different transplant eras. 
Statistical methods
Kaplan-Meier method was used to estimate survival as well 
as time to development of BOS-III. 
To estimate short and long-term predictive accuracy for 
each score, time dependent receiver operating characteristic 
curves (ROC) were applied, accounting for the fact that 
censoring was present. The time points shown in figures 
were 1 month, and 1, 5 and 10 years after transplantation. 
Areas under the ROC curves (AUC) were estimated at 
each of the pre-specified time points. To compare models’ 
goodness of fit, Akaike’s information criterion (AIC) was 
used, with lower AIC indicating better model fit. The AIC 
can be interpreted in such a way that a reduction of more 
than 2 points in the comparison of nested models would 
indicate a significantly better model fit, corresponding to a 
likelihood-ratio test.
For the development of a new score, multiple Cox 
proportional hazards models were used. The number of 
predictors allowed to be simultaneously in the multiple Cox 
models was based on the number of events (deaths). The 
general rule of ten events per variable in the prediction 
model was considered (14). To address the problem of over-
fitting, the estimated coefficients of the Cox model were 
shrinked globally, with a shrinkage factor estimated with 
the DFBETA method (15). In this context, global shrinkage 
means that the same amount of shrinkage was applied to 
all estimated parameters. The assessment of the shrinkage 
factor with the DFBETA method corresponds to leave-
one-out cross-validation (LOOCV) but is computationally 
more efficient. This aspect is of relevance especially when 
the number of observations is large as in this study (16). 
The closer the shrinkage factor to 1, the less shrinkage is 
required and the less over-fitting was determined. The Cox 
proportional hazards (PH) assumption was evaluated with 
a score test based on Schoenfeld residuals. In case that the 
proportional hazards assumption for a variable was violated, 
a suitable cut-off for the variable was derived, and the 
proportional hazards assumption was re-evaluated. 
For secondary outcomes, BOS-III was addressed with 
a Cox model in which non-survivors were censored, and 
the binary outcome PGD3 was addressed with a logistic 
regression model. All estimated coefficients were shown 
with 95% confidence intervals. All analyses were carried out 
with the statistical programming language R [R Core Team 
(2019)], version 3.6.0, and time-dependent ROC curves 
were fitted with the R-package “timeROC”. Shrinkage was 
performed with R-package “shrink”. 
The results of this study were presented in accordance 
with the TRIPOD guidelines (17) for reporting of clinical 
prediction models.
Results
In our cohort, there were 454 adult recipients with lung 
transplantation between 1991 and 2015, and with at least 
4 years follow-up. Of these, 320 recipients (70.5%) died. 
Median follow-up time was 14.2 years (95% confidence 
interval 12.4 to 16.0 years). No loss to follow-up occurred. 
Detailed descriptive statistics of recipient-, donor-, intra- 
and post-operative characteristics are shown in Table 1. 
More than 72% of all donors were non-ideal donors 
according to ISHLT consensus criteria (1) (Table 1). 
Validation of the five existing donor scores in our cohort
Factors for Oto-Donor-Score (2), Eurotransplant-Score (3), 
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Minnesota-Donor-Lung quality index (4), Maryland-
UNOS-data donor score (5) and Louisville-UNOS-data 
donor score (6) are illustrated in Tables S1-S5, respectively. 
Akaike’s information criterion revealed best model fit for 
predictability for Maryland-UNOS-data donor score with 
an AIC value of 3,414.4, followed by lower fit for Louisville-
UNOS-data donor score (AIC 3,414.9), Minnesota-Donor-
Lung quality index (AIC 3,417.8), Oto-Donor-Score (AIC 
3,425.1) and finally the lowest fit for Eurotransplant-Score 
(AIC 3,426.3). 
Development of the Zurich-Donor-Score
A multiple Cox model was used to evaluate the weight of 
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ICU admission pre-operative 43 (9.5%)
mPAP >25 mmHg 235 (51.8%)
Waitlist time (days), median (range) 150 (0–1,965)
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Extended criteria according to ISHLT (1)
Age ≥55 years 128 (28.2%)
Smoking history ≥20 packyears 77 (17.0%)
Chest X-Ray pathologic 122 (26.9%)
Bronchoscopy pathologic 50 (11.0%)
PaO2-FiO Ratio <300 mmHg 171 (37.7%)





Peri and post-operative characteristics
Unilateral transplantation 36 (7.9%)
Retransplantation 19 (4.2%)
ECMO use 186 (41.0%)
Donor cardiac after circulatory death 16 (3.5%)
Max. ischemic time (minutes), median 
(range)
334 (132–885)
ICU time (days), median (range) 4 (1–311)
PGD Grade3 at 72 hours 75 (16.5%)
PGD, primary graft dysfunction; CMV, Cytomegalovirus; 
ICU, intensive care unit; ECMO, extracorporal membrane 
oxygenation; mPAP, mean pulmonary artery pressure; CF, 
cystic fibrosis; IPF, interstitial pulmonary fibrosis; PPH, primary 
pulmonary hypertension; EMP, emphysema.
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significant pulmonary infection, diabetes mellitus, PAO2/
FiO2-ratio (in categories with breaks at 300 and 150 mmHg), 
smoking history (in categories with breaks at 20 and 
50 pack years), and donor age (with breaks at 50 and 
70 years). The breaks in the continuous variables were 
justified from fitting multiple non-linear Cox models using 
splines (Figure 1) and by the literature. After the multiple 
Cox model was fitted based on the categorical variables, 
there was some indication for overfitting, resulting in a 
global estimated shrinkage factor of 0.82. The new score 
varied between 0 (low mortality risk) and 12 (high mortality 
risk) in our sample, whereas mean and median of the new 
score were 3.3 and 3. Details can be found in Table 2. 
Figure 2A and Table 3 show the results of a time-dependent 
ROC analysis of the new Zurich-Donor-Score as compared 
to the existing donor scores. The AIC value of the Zurich-
Donor-Score was 3,398.9, which was lower than those of all 
existing donor score, indicating better model fit. 
Assessing the predictive accuracy of all donor scores while 
adjusting for recipient and surgical procedure variables 
Recipient and surgical procedure variables included 
unilateral transplantation, retransplantation, idiopathic 
pulmonary fibrosis as underling disease, preoperative 
intensive care unit stay, recipient age, and age independent 
Charlson-Deyo Index. Figure 2B showed that recipient 
and surgical procedure variables are crucial in order to 
make predictions of survival over time. After one month, 
donor and receiver information seem to be almost equally 
important, but as time passes, recipient and surgical 
procedure information from baseline become more 
important, leading to a substantially improved AUC for 
all scores at 10 years follow-up time. In a multiple Cox 
model with adjustment for recipient and surgical procedure 
variables, the estimated hazard ratio for the new score was 
1.14 (95% CI: 1.09 to 1.19, P<0.001) per point increase. 
Secondary outcomes: time to BOS-III and PGD3
Although the new donor score was originally developed 
for the short- and long-term prediction of mortality after 
lung transplantation, the score may also be evaluated for 
the secondary outcomes BOS-III and PGD3. BOS-III was 
developed by 168 (37%) of the recipients. In a multiple Cox 
model with adjustment for recipient and surgical procedure 
variables, the estimated hazard ratio for the new score was 
1.14 (95% CI: 1.07 to 1.21, P<0.001) per point increase. 
Seventy-five percent recipients (17%) experienced PGD3. 
When the new score was evaluated in a multiple logistic 
regression model with PGD3 as outcome, again adjusting 
for recipient and surgical procedure variables, the estimated 
odds ratio was 1.13 (95% CI: 1.03 to 1.23, P=0.01).
Discussion
Our study validates five existing donor scores in terms 
of short- and long-term survival, which were originally 
Figure 1 Additive non-linear effects using splines of the continuous variables in multiple Cox regression models. (A) Smoking history, (B) 
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Table 2 Development of Zurich Donor Score based on estimated β-coefficients from multiple Cox model and shrinked coefficients
Predictor N HR (95% CI) β Shrinked β
Score points Zurich donor 
score (total 17 points)
Significant pulmonary infection*
Yes 127 1.46 (1.14–1.87) 0.38 0.31 3
No 327 – – – 0
Diabetes mellitus
Yes 25 1.29 (0.80–2.10) 0.25 0.21 2
No 429 – – – 0
PaO2/FiO2-ratio (mmHg)
>300 278 – – – 0
300 to >150 134 1.30 (1.01–1.66) 0.26 0.21 2
≤150 42 1.50 (1.22–1.87) 0.4 0.33 3
Smoking history (pack years)
<20 377 – – – 0
20 to <50 69 1.43 (0.60–3.50) 0.36 0.29 3
≥50 8 1.63 (1.22–2.18) 0.49 0.4 4
Age (years)
<50 273 – – – 0
50 to <70 151 1.31 (1.02–1.68) 0.27 0.22 2
≥70 30 2.24 (1.44–3.50) 0.81 0.66 5
β, β-coefficient; CI, confidence interval; HR, hazard ratio. *Radiological suspicion of pneumonia, bronchoscopic sign of severe bronchitis, 
history of aspiration (radiological suspicion of pneumonia: opacity in one or more lobes not predominantly resembling in morphology to 
atelectasis or edema; Signs of severe bronchitis: purulent secretions and/or signs of bronchial inflammation in bronchoscopy; History of 
aspiration: observed aspiration, signs in bronchoscopy of aspiration or a history highly suspicious of aspiration). 
Figure 2 Time dependent AUC values for the five existing donor scores and the new Zurich-Donor-Score. (A) Unadjusted, based on donor 
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developed to simplify donor selection and to predict short- 
to mid-term survival. In addition, we propose a new and 
simple scoring system that is well adapted for the current 
urge of extended donor use and shows higher discriminative 
ability for short- to long-term survival. 
Our transplant center in Switzerland has long-term 
experience in utilizing extended criteria donor lungs (18). 
The recent lung acceptance rate of 46% is higher than in 
most other European centers and the United States, but the 
long-term survival results are comparable (19). More than 
70% of all recipients in our study received a not ideal donor 
lung based on the ISHLT-consensus criteria (1), offering 
good conditions for validation of existing donor scores and 
the derivation of a new scoring system.
Qualitative summary of the existing donor scores
The relatively complex donor scoring systems of Oto (2), 
Eurotransplant (3) and Minnesota (4), which were originally 
created to predict donor selection, lead to a slightly poorer 
prediction of short- and long-term survival as did the simple 
Maryland-UNOS-data (5) and Louisville-UNOS-data 
score (6), which were derived to predict short-term survival 
and mid-term survival, respectively. 
Qualitative summary of the Zurich-Donor-Score
For our new and simple extended donor prediction score, 
we identified and weighted five donor risk factors that 
are available at the time of donor selection: age (breaks at 
≥50 and ≥70 years), smoking history (breaks at ≥20 and 
≥50 pack years), significant pulmonary infection, insulin 
dependent diabetes mellitus and PaO2/FiO2-ratio (breaks at 
≤300 and ≤150 mmHg).
Increasing donor age has an increasing negative impact 
on survival according to our findings which is comparable 
with the recent ISHLT-Registry Report (12). Our lower 
break of 50 or more years fits the start of risk of a large 
study using the UNOS-Database (20). 
The observed increasing risk with increasing donor 
smoking history fits the idea of the donor scoring systems 
of Oto (2). The lower break of 20 or more pack years is 
in agreement with the ISHLT-consensus criteria (1) and a 
recent study using UNOS-Data (4). 
Our risk factor of a significant pulmonary infection 
includes radiological findings suspicious of pneumonia, 
bronchoscopic signs of severe bronchitis and history 
of aspiration. These were defined as extended criteria 
according to ISHLT-consensus report (1). We combined 
and reduced these criteria, as their impact is to a certain 
extent controversial. Some studies have pointed out that 
lungs with radiological hints of pulmonary infiltrates did 




30 days 0.56 0.06
1 year 0.59 0.04
5 years 0.64 0.03
10 years 0.66 0.03
Eurotransplant Score (3)
30 days 0.51 0.06
1 year 0.54 0.03
5 years 0.58 0.03
10 years 0.61 0.03
Oto Donor Score (2)
30 days 0.51 0.06
1 year 0.56 0.04
5 years 0.58 0.03
10 years 0.6 0.03
Minnesota-Donor-Lung quality index (4)
30 days 0.47 0.06
1 year 0.55 0.04
5 years 0.6 0.03
10 years 0.62 0.03
Maryland-UNOS-data donor score (5)
30 days 0.58 0.05
1 year 0.54 0.03
5 years 0.6 0.02
10 years 0.58 0.02
Louisville-UNOS-data donor score (6)
30 days 0.56 0.06
1 year 0.53 0.04
5 years 0.59 0.03
10 years 0.64 0.03
AUC, area under the ROC curve; SE, standard error.
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not affect transplant survival (21,22). Other studies showed 
that radiological abnormalities and additional purulent 
bronchoscope secretion (23) and radiological abnormalities 
and additional reduced gas exchange (18) did increase 
mortality.
Donor diabetes mellitus is a widely accepted (5,12) risk 
factor, even though the pathophysiology is not yet clearly 
known (24).
Our detected risk of a declining PaO2/FiO2-ratio form 
300 mmHg downwards fits the recommendation of the 
ISHLT-consensus criteria (1). While a multicenter study 
found an impact (25), data from UNOS (26) suggest partial 
pressure of oxygen levels of lower than 200 mmHg do not 
affect graft survival. That’s why we weighted this factor 
proportionally low in our score.
Our final Zurich-Donor-Score showed better prediction 
of 1 to 10-year survival in comparison to the five existing 
scores. 
Although this new donor score was originally developed 
for the short- and long-term prediction of mortality after 
lung transplantation, the score also showed predictability for 
development of BOS-III and PGD3. This may be explained 
to a certain extent by the incorporated risk factors of age 
and smoking history. Older age was identified as a risk 
factor for BOS-III in some studies (27,28), while it is still 
controversial in causing PGD3 (29,30). Any donor smoking 
was reported to have an association with BOS-III (27) 
and a negative impact on PGD3 (31). The significance of 
donor lung infection for PGD3 is not yet understood (32).
Limitations and strengths
This study has several limitations. It is a retrospective 
single-center study over more than two decades, however 
without an era effect in univariable and multiple analyses, 
even though we stratified in different models up to 3 eras. 
All donor variables and subsequent calculation of scores 
are based on pre-procurement parameters. Although we 
did not find any discrepancies between these values and the 
donor lung reports at the time of retrieval, the values might 
not account for exact results of the physical examination 
of the lung at the time of retrieval (33). We acknowledge 
that variables such as the interpretations of chest X-ray and 
bronchoscopy are to some extent subjective. As our data 
collection is limited, there might have been some other 
important donor variables, which were not found to be 
important, because their prevalence was low in our setting. 
For example, we were not able to include data from the 
African race, a variable which is part of the Maryland- and 
Louisville-UNOS-data donor score. We also acknowledge 
that performance of the original Minnesota-Donor-Lung 
quality index including LAS might have been superior to 
our compensative adjustment for recipient and surgical 
procedure variables. Our study has several strengths: 
we used shrinkage of estimated coefficients prior to 
the development of the new score, a method to reduce 
overfitting that would otherwise lead to low predictive 
performance in new data sets. Consequently, this approach 
of shrinkage manages to already preclude optimism of the 
score without the need of a separate validation cohort.
Conclusions 
The proposed Zurich-Donor-Score is a simple scoring 
system of five objective and easily available pre-procurement 
donor variables. The new score shows higher discriminative 
ability when compared to existing donor scores regarding 
short- to long-term survival. This score is not yet evaluated 
for organ acceptance; this is currently being studied. In the 
reality of severe organ shortage and urge for more extended 
grafts, our proposed new score may be useful for clinical 
decision making in donor selection, allocation to specific 
recipient populations, comparison of data across centers, 
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Supplementary
Table S1 Oto-Donor-Score (2)
Points (total 18 points) Cohort (N=454)
Univariable Cox regression
HR; 95% CI P value
Age (years)
<45 0 221 (48.7%) –
45–54 1 105 (23.1%) 1.1; 0.8–1.4 0.5
55–59 2 48 (10.6%) 1.4; 1.0–2.0 0.05
≥60 3 80 (17.6%) 1.5; 1.1–1.9 0.01
Smoking history (pack-years)
<20 0 377 (83.0%) –
20–39 1 56 (12.3%) 1.6; 1.2–2.2 0.002
40–59 2 16 (3.5%) 1.7; 1.0–2.9 0.06
≥60 3 5 (1.1%) –
Chest X-ray
Clear 0 245 (54.0%) –
Minor 1 90 (19.8%) 0.9; 0.8–1.2 0.6
Opacity ≤1 lobe 2 64 (14.1%) 1.0; 0.8–1.3 0.7
Opacity >1 lobe 3 55 (12.1%) 1.0; 0.7–1.4 0.9
Secretions in bronchoscopy
None 0 384 (84.6%) –
Minor 1 23 (5.1%) 1.2; 0.9–1.7 0.2
Moderate 2 17 (3.7%) 1.2; 0.8–1.8 0.3
Major 3 30 (6.6%) 1.7; 1.1–2.7 0.02
PaO2/FiO2 (mmHg)
>450 0 90 (19.8%) –
351–450 2 139 (30.6%) 0.9; 0.7–1.2 0.7
301–350 4 55 (12.1%) 0.8; 0.6–1.2 0.4
≤300 6 170 (37.4%) 1.2; 1.0–1.5 0.08
CI, confidence interval; HR, hazard ratio.
Table S2 Eurotransplant-Score (3)
Points (total 19 points) cohort (N=454)
Univariable Cox regression
HR; 95% CI P value
Age (years)
<45 and 45–54 1 326 (71.8%) –
55–59 2 48 (10.6%) 1.4; 1.0–2.0 0.05
≥60 3 80 (17.6%) 1.5; 1.1–1.9 0.01
Smoking history (pack-years)
Yes 2 277 (61.0%) –
No 1 177 (39.0%) 1.2; 1.0–1.6 0.06
Chest X-ray
Clear, Edema or Atelectasis 1 335 (73.8%) –
Shadow or Consolidation 2 119 (26.2%) 1.0; 0.8–1.3 0.9
Secretions in bronchoscopy
Clear or nonpurulent 1 405 (89.2%) –
Purulent 2 27 (5.9%) 1.1; 0.8–1.7 0.5
Inflammation 3 22 (4.8%) 1.6; 1.0–2.7 0.05
Visualized tumor 5 - –
PaO2/FiO2 (mmHg)
>450 and 351–450 1 216 (47.6%) –
301–350 2 68 (15.0%) 0.8; 0.6–1.2 0.4
≤300 3 170 (37.4%) 1.2; 1.0–1.5 0.08
Donor history
Compromised* 4 28 (6.2%) 1.1; 0.9–1.2 0.4
Uncompromised 1 426 (93.8%) –
CI, confidence interval; HR, hazard ratio. *The donor history is compromised in case of malignancy, sepsis, drug abuse, meningitis, or a 
positive virology was registered
Table S3 Minnesota-Donor-Lung quality index (4)




HR; 95% CI P value
1. Anticipated ischemic time
<6 hours 1 404 (89.0%) –
≥6 hours 0 50 (11.0%) 1.0; 0.7–1.4 0.9
2. Risk of pneumonia
Low 4 173 (38.1%) –
Moderate 2 232 (51.1%) 1.0; 0.8–1.2 0.9
High 0 49 (10.8%) 1.1; 1.0–1.1 0.2
3. Donor age
15–45 years 2 234 (51.5%) –
46–65 years 1 178 (39.2%) 1.2; 0.9–1.5 0.1
>65 years 0 42 (9.3%) 1.9; 1.3–2.7 0.001
4. Risk of aspiration injury
Low 3 411 (90.5%) –
Moderate 2 28 (6.2%) 1.2; 0.8–1.7 0.4
High 0 15 (3.3%) 1.4; 0.7–2.9 0.3
5. Risk of preexisting lung disease
Low 4 446 (98.2%) –
Moderate 2 8 (1.8%) 1.0; 0.8–1.2 0.9
High 0 – –
6. Risk of pulmonary edema
Low 3 447 (98.5%) –
Moderate 2 7 (1.5%) 1.7; 0.8–3.7 0.1
High 0 – –
7. Risk of contusion
Low 2 428 (94.3%) –
Moderate 1 15 (3.3%) 0.7; 0.5–1.2 0.2
High 0 11 (2.4%) 1.0; 0.5–2.0 0.9
8. Blood gasses
Good 3 284 (62.6%) –
Marginal 0 170 (37.4%) 0.9; 0.9–1.0 0.05
9. Smoking history
<30 Pack-years 2 397 (87.4%) –
≥30 Pack-years 0 57 (12.8%) 1.7; 1.2–2.3 0.001
10. Anticipated procurement complexity
Simple 2 415 (91.4%) –
Moderate 1 36 (7.9%) 1.0; 0.6–1.5 0.9
Complex 0 3 (0.7%) –
11. Risk of pulmonary malignancy
Low 5 283 (62.3%) –
Moderate 4 94 (20.7%) 1.1; 0.8–1.4 0.7
High 0 77 (17.0%) 1.6; 1.2–2.1 0.001
12. Risk of donor-transmitted diseases
Low 4 452 (99.6%) –
Moderate 3 2 (0.4%) –
High 0 – –
13. Risk of extrapulmonary malignancy
Low 5 445 (98.0%) –
Moderate 2 9 (2.0%) 0.9; 0.7–1.1 0.2
High 0 –
14. Risk of positive retrospective HLA crossmatch
Low 5 454 (100%) –
Moderate 3 –
High 0 –
15. Risk of size missmatch
Low 3 294 (64.8%)
Moderate 2 23 (5.1%) 1.1; 0.9–1.4 0.3
High 0 137 (30.2%) 1.3; 1.0–1.6 0.06
CI, confidence interval; HLA, human leukocyte antigen; HR, hazard ratio.
Table S4 Maryland-UNOS-data donor score (5)
Points (total 4 points) Cohort (N=454)
Univariable Cox regression
HR; 95% CI P value
Age ≥65 years 1 42 (9.3%) 1.9; 1.3–2.7 0.001
Smoking history ≥20 packyears 1 77 (17.0%) 1.7; 1.3–2.2 <0.001
Diabetes 1 25 (5.5%) 1.8; 1.1–2.9 0.01
African American race 1 – –
CI, confidence interval; HR, hazard ratio.
Table S5 Louisville-UNOS-data donor score (6)
Points (total 5 points) Cohort (N=454)
Univariable Cox regression
HR; 95% CI P value
Age, years
51–60 1 97 (21.4%) 1.3; 1.0–1.7 0.05
>60 2 71 (15.6%) 1.5; 1.5–2.1 0.005
Smoking history >20 packyears 1 77 (17.0%) 1.7; 1.3–2.2 <0.001
Diabetes 1 25 (5.5%) 1.8; 1.1–2.9 0.01
African American race 1 – –
CI, confidence interval; HR, hazard ratio.
